Home Healthcare Biotechnology Natural Killer (NK) Cell Therapeutics Market

Natural Killer (NK) Cell Therapeutics Market Size, Share & Trends Analysis Report By Product (CAR-NK Cell Therapies, NK Cell-directed Antibodies), By Indication (Oncology, Infectious Diseases, Autoimmune Diseases, Gastrointestinal Diseases, Other Indications), By End User (Hospitals & Clinics, Research & Academic Institutes, Other End Users) and By Country (U.S., Canada) Forecasts, 2026-2034

Last Updated: July 09, 2026 | Author: Mitiksha Koul | Format: | Report Code: SR4226DR | Pages: 150
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Natural Killer (NK) Cell Therapeutics Market, By Product 2022-2034 (USD MILLION/ Units)
    1. CAR-NK Cell Therapies
    2. NK Cell-directed Antibodies
  2. Natural Killer (NK) Cell Therapeutics Market, By Indication 2022-2034 (USD MILLION/ Units)
    1. Oncology
    2. Infectious Diseases
    3. Autoimmune Diseases
    4. Gastrointestinal Diseases
    5. Other Indications
  3. Natural Killer (NK) Cell Therapeutics Market, By End User 2022-2034 (USD MILLION/ Units)
    1. Hospitals & Clinics
    2. Research & Academic Institutes
    3. Other End Users
  4. Regional Natural Killer (NK) Cell Therapeutics Market
    1. North America
      1. North America Natural Killer (NK) Cell Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
      2. North America Natural Killer (NK) Cell Therapeutics Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Infectious Diseases
        3. Autoimmune Diseases
        4. Gastrointestinal Diseases
        5. Other Indications
      3. North America Natural Killer (NK) Cell Therapeutics Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research & Academic Institutes
        3. Other End Users
      4. U.S.
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      5. Canada
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
    2. Europe
      1. Europe Natural Killer (NK) Cell Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
      2. Europe Natural Killer (NK) Cell Therapeutics Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Infectious Diseases
        3. Autoimmune Diseases
        4. Gastrointestinal Diseases
        5. Other Indications
      3. Europe Natural Killer (NK) Cell Therapeutics Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research & Academic Institutes
        3. Other End Users
      4. U.K.
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      5. Germany
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      6. France
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      7. Spain
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      8. Italy
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      9. Russia
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      10. Nordic
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      11. Benelux
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      12. Rest of Europe
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
    3. APAC
      1. APAC Natural Killer (NK) Cell Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
      2. APAC Natural Killer (NK) Cell Therapeutics Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Infectious Diseases
        3. Autoimmune Diseases
        4. Gastrointestinal Diseases
        5. Other Indications
      3. APAC Natural Killer (NK) Cell Therapeutics Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research & Academic Institutes
        3. Other End Users
      4. China
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      5. Korea
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      6. Japan
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      7. India
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      8. Australia
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      9. Taiwan
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      10. South East Asia
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      11. Rest of Asia-Pacific
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
    4. Middle East and Africa
      1. Middle East and Africa Natural Killer (NK) Cell Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
      2. Middle East and Africa Natural Killer (NK) Cell Therapeutics Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Infectious Diseases
        3. Autoimmune Diseases
        4. Gastrointestinal Diseases
        5. Other Indications
      3. Middle East and Africa Natural Killer (NK) Cell Therapeutics Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research & Academic Institutes
        3. Other End Users
      4. UAE
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      5. Turkey
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      6. Saudi Arabia
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      7. South Africa
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      8. Egypt
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      9. Nigeria
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      10. Rest of MEA
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
    5. LATAM
      1. LATAM Natural Killer (NK) Cell Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
      2. LATAM Natural Killer (NK) Cell Therapeutics Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Infectious Diseases
        3. Autoimmune Diseases
        4. Gastrointestinal Diseases
        5. Other Indications
      3. LATAM Natural Killer (NK) Cell Therapeutics Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research & Academic Institutes
        3. Other End Users
      4. Brazil
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      5. Mexico
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      6. Argentina
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      7. Chile
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      8. Colombia
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
      9. Rest of LATAM
        1. CAR-NK Cell Therapies
        2. NK Cell-directed Antibodies
        3. Oncology
        4. Infectious Diseases
        5. Autoimmune Diseases
        6. Gastrointestinal Diseases
        7. Other Indications
        8. Hospitals & Clinics
        9. Research & Academic Institutes
        10. Other End Users
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.